ALHC President Maroney Dawn Christine Sells $586K of Stock
Alignment Healthcare's President sold shares worth $586,500 in a planned transaction.
Reviewed by automated data checks against the source filing. How we make and check alerts
Maroney Dawn Christine, President at Alignment Healthcare, Inc. ($ALHC), sold 30,000 shares at an average price of $19.55, worth about $586,500, on June 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $ALHC is up 7.6% after 1 week, up 5.8% after 1 month and down 58.1% to date (from the $19.78 close on Jun 15, 2026).
ALHC
Alignment Healthcare, Inc.
Key Points
- Maroney Dawn Christine, President of Alignment Healthcare, sold 30,000 shares at $19.55 each, totaling $586,500 on June 15, 2026.
- Alignment Healthcare, Inc. (NasdaqGS: ALHC) trades near $19.75 with a market cap of $4.08 billion and a P/E ratio of 197.5.
- Major funds like Wellington Management and FMR LLC increased their stakes in Alignment, indicating institutional interest.
Get $ALHC trade alerts by text
We text you when insiders, Congress or big funds trade $ALHC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alignment Healthcare, Inc. alert may contain errors. Disclosures
Maroney Dawn Christine, President of Alignment Healthcare, Inc. (NasdaqGS: ALHC), sold 30,000 shares of the company on June 15, 2026. The shares were sold at an average price of $19.55, amounting to a total value of $586,500. This transaction was part of a pre-planned trading strategy under Rule 10b5-1.
Other Institutional Activity in Alignment Healthcare
In recent institutional activity, Wellington Management Group LLP increased its holdings in Alignment Healthcare by 3,028,043 shares, ending with 17,098,936 shares valued at approximately $301.3 million. FMR LLC also added 1,236,129 shares, bringing its total to 15,892,064 shares worth about $280 million. BlackRock, Inc. grew its stake by 363,883 shares, reaching a total of 14,075,197 shares valued at $248 million. T. Rowe Price Investment Management, Inc. increased its position by 503,872 shares, now holding 13,147,656 shares valued at $231.7 million.
Alignment Healthcare, Inc. Stock Up 139.5%
Shares of Alignment Healthcare (NasdaqGS: ALHC) are trading near $19.75. The company has a market capitalization of $4.08 billion and a high P/E ratio of 197.5, indicating investor expectations of future growth. The stock's 52-week range is between $11.63 and $23.87, with a beta of 1.149, suggesting moderate volatility. The 50-day moving average is $18.62, and the 200-day moving average is $18.61. Alignment Healthcare maintains a current ratio of 1.58 and a quick ratio of 1.385, with a debt-to-equity ratio of 159.492.
Recent Earnings
Alignment Healthcare reported revenue of $4.26 billion, reflecting a growth rate of 33.3%. The company posted an EPS of $0.10, with a net margin of 0.465% and a return on equity of 12.53%. The next earnings report is expected on July 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
1 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 575.7%. Revenue missed estimates by 0.5%.
-
Profit surprise
EBITDA missed by 28 percent. Operating income missed by 3 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 1 target cut.
-
Earnings quality
Operating margin up 1.8 points. Negative free cash flow.
Earnings Call Summary
Alignment Healthcare reported first quarter 2026 revenue of $1.2 billion, up 33 percent year over year, driven by strong membership growth of 31 percent to 284,800 members. The company beat adjusted EBITDA expectations at $38 million, exceeding guidance range. Management highlighted a temporary January billing issue related to observation versus acute rate payments that caused higher inpatient admissions in early Q1, but stated the problem was internal, quickly resolved by February, and did not signal a systemic flaw. Management remained confident in scaling to 1 million members and emphasized continuous improvement in claims automation, AI deployment, and clinical efficiency.
Guidance Alignment raised its full year revenue guidance to approximately $5.2 billion, up from prior outlook, expecting 31 percent growth. The company also raised adjusted EBITDA guidance, projecting between $138 million and $163 million for 2026. For the second quarter, they guided revenue between $1.3 billion and $1.32 billion and EBITDA of $50 million to $60 million. Management emphasized confidence in delivering the first half at strong margins while continuing investments in automation and clinical infrastructure.
Underwhelming report. Mixed results that may lead to slightly lower expectations.
Insider Buying and Selling at Alignment Healthcare, Inc.
In addition to Maroney's sale, several other insiders have recently transacted shares. On June 12, 2026, Chief Medical Officer Hyong Kim sold 35,951 shares at $19.86 each. On June 11, 2026, Joseph Konowiecki, EVP of Corporate Affairs, sold 25,000 shares at $21.00. CEO John Kao sold 298,000 shares at $20.36 on June 10, 2026. Earlier, on June 3, 2026, Joseph Konowiecki and Mark Kent, President - MSO, acquired 122,807 and 87,719 shares, respectively.
Analysts Set New Price Targets
On May 26, 2026, Barclays maintained its 'hold' rating on Alignment Healthcare with a price target of $16. UBS also kept a 'hold' rating on May 1, 2026, with a target of $22. JP Morgan reiterated a 'buy' rating on February 5, 2026, with a target of $26. According to 13 analyst opinions, the consensus recommendation is a 'strong buy', with a mean target price of $24.92.
About Alignment Healthcare
Alignment Healthcare, Inc. operates a healthcare platform tailored for seniors in the United States, offering Medicare Advantage plans. Founded in 2013 and based in Orange, California, the company aims to provide a personalized healthcare experience for seniors. It is led by CEO John E. Kao and employs around 1,849 people.
Bottom Line
Maroney Dawn Christine's planned stock sale is one of several insider transactions at Alignment Healthcare, reflecting ongoing activity within the company's leadership. The company's high P/E ratio and substantial market cap suggest strong investor interest, while recent institutional investments highlight confidence in its growth prospects. As always, remember that insider trading reports are backward-looking and may not reflect current positions.
Related Filing Alerts
Source: Maroney Dawn Christine's Form 4 filing on $ALHC (Jun 15, 2026). Find the original filing: ALHC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts